X

AptarGroup, Inc (ATR) Aptar’s Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN Nasal Spray

AptarGroup, Inc (NYSE: ATR) FY 2026 Other Release

Newsdesk: